EYEG - EyeGate Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.6276
+0.0040 (+0.64%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close0.6236
Open0.6400
Bid0.0000 x 3000
Ask0.0000 x 800
Day's Range0.6025 - 0.6400
52 Week Range0.2900 - 2.0200
Volume299,959
Avg. Volume1,383,503
Market Cap26.287M
Beta3.26
PE Ratio (TTM)N/A
EPS (TTM)-0.9270
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.67
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    EyeGate Addresses Majority of FDA’s Action Items with Submission of Investigational Device Exemption Amendment for Ocular Bandage Gel

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that it has addressed three of the four outstanding items in a Second Amendment in response to the U.S. Food and Drug Administration’s (FDA) review of its first amendment. EyeGate has demonstrated continued progress towards achieving the Investigational Device Exemption (IDE) for a second pilot study of the Company’s Ocular Bandage Gel (OBG) product, a cross-linked thiolated carboxymethyl hyaluronic acid (CMHA-S) platform being developed for the acceleration of re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK).

  • GlobeNewswire7 days ago

    EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that Steven Boyd has joined its board. Paul Chaney, EyeGate’s Chairman, said, “We are pleased to welcome Steven Boyd to the Board of EyeGate. Mr. Boyd said, “I am excited to join the Board of a company like EyeGate with two unique and proprietary platforms that I strongly believe in.

  • GlobeNewswire13 days ago

    EyeGate Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced financial results for the three-month period ended March 31, 2018, and provided an update on recent corporate and operational activities. “During the first quarter of 2018, we were able to reinforce our core platforms at EyeGate with several strategic accomplishments, as well as operational achievements that help solidify our direction moving forward,” said Stephen From, President and Chief Executive Officer of EyeGate Pharmaceuticals. “Regarding EyeGate’s clinical operations,” Mr. From continued, “Our clinical story has advanced with the submission of the investigation device exemption (IDE) amendment for the second pilot study of ocular bandage gel (EyeGate OBG), which summarized the company’s response to the original IDE.

  • Are Insiders Too Confident In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)?
    Simply Wall St.17 days ago

    Are Insiders Too Confident In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)?

    EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. EyeGate Pharmaceuticals is one of United States’s small-capRead More...

  • GlobeNewswirelast month

    EyeGate Announces Completion of $11.25 Million Public Offering

    WALTHAM, Mass., April 17, 2018-- EyeGate Pharmaceuticals, Inc., a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, ...

  • GlobeNewswirelast month

    EyeGate Announces $11.25 Million Public Offering

    WALTHAM, Mass., April 13, 2018-- EyeGate Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the ...

  • GlobeNewswirelast month

    EyeGate Issued New Patent for Iontophoretic Contact Lens Technology

    WALTHAM, Mass., April 11, 2018-- EyeGate Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the ...

  • GlobeNewswirelast month

    EyeGate Receives FDA Feedback on Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel

    WALTHAM, Mass., April 09, 2018-- EyeGate Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the ...

  • GlobeNewswire2 months ago

    EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis

    WALTHAM, Mass., April 06, 2018-- EyeGate Pharmaceuticals, Inc., today announced completion of patient enrollment for the pivotal Phase 3 clinical study of its EGP-437 combination product for the treatment ...

  • GlobeNewswire2 months ago

    EyeGate Pharma To Participate At The 30TH Annual ROTH Conference

    WALTHAM, Mass., March 09, 2018-- EyeGate Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the ...

  • EyeGate Pharmaceuticals Inc (NASDAQ:EYEG): Poised For Long-Term Success?
    Simply Wall St.2 months ago

    EyeGate Pharmaceuticals Inc (NASDAQ:EYEG): Poised For Long-Term Success?

    The most recent earnings update EyeGate Pharmaceuticals Inc’s (NASDAQ:EYEG) released in December 2017 confirmed company earnings became less negative compared to the previous year’s level as a result of recentRead More...

  • GlobeNewswire3 months ago

    EyeGate Pharma Submits Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel

    WALTHAM, Mass., March 08, 2018-- EyeGate Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the ...

  • GlobeNewswire3 months ago

    EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results and Provides Business Update

    WALTHAM, Mass., March 02, 2018-- EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders ...

  • Zacks Small Cap Research3 months ago

    EYEG: Cataract Surgery Phase II Topline Data: Efficacy Signal Despite Miss to Primary Endpoint

    Earlier this month EyeGate (EYEG) announced top-line results of its phase IIb study evaluating the safety and efficacy of EGP-437 in patients which underwent cataract surgery with implantation of a monofocal posterier chamber intra-ocular lens (IOL).  Primary efficacy endpoint is the proportion of subjects with an anterior chamber (AC) cell count of zero at Day 7 and the proportion of subjects with pain score of zero at Day 1.  Secondary endpoints are change in mean ACC on Day 7 and change in mean pain score on Day 1.

  • What Spooked Eyegate Pharmaceuticals Inc Investors Today
    SmarterAnalyst4 months ago

    What Spooked Eyegate Pharmaceuticals Inc Investors Today

    The stock's double-digit nosedive was sparked by disappointing top-line results from a phase 2b trial of the company's EGP-437 combination product for pain and inflammation in patients having undergone cataract surgery. Eyegate reported that the co-primary endpoints of proportion of subjects with an anterior chamber cell (ACC) count of zero at day 7 and the proportion of subjects with a pain score of zero at day 1 did not show statistical significance. “The efficacy results for the absence of inflammatory cells in the EGP-437 treatment group met our expectations, but the vehicle group response was better than anticipated.

  • Should You Worry About Eyegate Pharmaceuticals Inc’s (NASDAQ:EYEG) CEO Pay Check?
    Simply Wall St.4 months ago

    Should You Worry About Eyegate Pharmaceuticals Inc’s (NASDAQ:EYEG) CEO Pay Check?

    Stephen From is the CEO of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG), which has recently grown to a market capitalization of $20.65M. Recognizing whether CEO incentives are aligned with shareholders is aRead More...

  • With A -14.24% Earnings Drop Lately, Did Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) Underperform Its Industry?
    Simply Wall St.5 months ago

    With A -14.24% Earnings Drop Lately, Did Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) Underperform Its Industry?

    Understanding how Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) is performing as a company requires looking at more than just a years’ earnings. Today I will run you through a basic sense checkRead More...

  • Capital Cube5 months ago

    ETFs with exposure to EyeGate Pharmaceuticals, Inc. : December 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to EyeGate Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to EYEG-US. Comparing the performance and risk of EyeGate Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • What Does Eyegate Pharmaceuticals Inc’s (EYEG) Share Price Indicate?
    Simply Wall St.6 months ago

    What Does Eyegate Pharmaceuticals Inc’s (EYEG) Share Price Indicate?

    Eyegate Pharmaceuticals Inc (NASDAQ:EYEG), a pharmaceuticals company based in United States, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqCM. LessRead More...